ML-193

CAT: 0804-HY-110125-01Size: 5 mgDry Ice: NoHazardous: No
CAT#:0804-HY-110125-01Size:5 mg
Selected
AVAILABILITY: InStock
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Product image 1
1 / 1
Description
ML-193 (CID 1261822) is a potent and selective antagonist of GPR55, with an IC50 of 221 nM. ML-193 shows more than 27-fold selectivity for GPR55 over GPR35, CB1 and CB2. ML-193 can improve the motor and the sensorimotor deficits of Parkinson’s disease (PD) rats[1][2][3].
CAS Number
[713121-80-3]
Product Name Alternative
CID 1261822
UNSPSC
12352005
Hazard Statement
H302, H315, H319, H335
Target
GPR55
Type
Reference compound
Related Pathways
GPCR/G Protein; Neuronal Signaling
Applications
Neuroscience-Neurodegeneration
Field of Research
Neurological Disease
Assay Protocol
https://www.medchemexpress.com/ml-193.html
Purity
99.82
Solubility
DMSO : 100 mg/mL (ultrasonic)
Smiles
CC(C(C)=NO1)=C1NS(C(C=C2)=CC=C2NC(C3=CC(C4=CC=CC=N4)=NC5=C3C=C(C)C=C5C)=O)(=O)=O
Molecular Formula
C28H25N5O4S
Molecular Weight
527.59
Precautions
H302, H315, H319, H335
References & Citations
[1]Heynen-Genel S, et, al. Screening for Selective Ligands for GPR55-Antagonists. Probe Reports from the NIH Molecular Libraries Program. 2010 Oct 30.|[2]Kotsikorou E, et, al. Identification of the GPR55 antagonist binding site using a novel set of high-potency GPR55 selective ligands. Biochemistry. 2013 Dec 31;52 (52) :9456-69.|[3]Fatemi I, et, al. The effect of intra-striatal administration of GPR55 agonist (LPI) and antagonist (ML193) on sensorimotor and motor functions in a Parkinson's disease rat model. Acta Neuropsychiatr. 2021 Feb;33 (1) :15-21.|[4]Hill JD, et, al. Activation of GPR55 increases neural stem cell proliferation and promotes early adult hippocampal neurogenesis. Br J Pharmacol. 2018 Aug;175 (16) :3407-3421.
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Reference compound1
Clinical Information
No Development Reported

Popular Products